Did you know?
ChinaBio® LLC is a consulting and advisory firm that helps Western companies come to China. We assist our clients with China strategy development, market research and analysis, partner/technology searches, competitive surveys, and market entry planning.

>> Learn more…
Site Search

>> Advanced Search

  Quick Search:
 
 

Free Newsletter

  Email address:
   

Simcere to Develop Cancer Drug from OSI Pharma in China

publication date: Oct 20, 2009
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.

Simcere Pharmaceutical Group (先声药业) has acquired the China rights to a dual-mechanism cancer drug from OSI Pharmaceuticals. Simcere must first obtain regulatory approval for OSI-930, and then it will produce and market the drug in China. In the US, OSI-930 has completed a Phase I trial. Terms of the agreement were not disclosed. More details...

Stock Symbols: (NYSE: SCR) (NSDQ: OSIP)




Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...

Login

  

    
   
Partner Events

China Medical Affairs Summit
June 12-13, 2014
Shanghai, China


>>More events...
Our Partners
Annual Sponsors
 
Official Partners
 
Supporting Partners
 
Media Partners